The White House announced nine additional most-favored-nation (MFN) pricing agreements with midsized drugmakers, bringing the total to 26 participating manufacturers that the government says cover 89% of the branded drug market. The signatories include Alcon, Astellas, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva, and UCB. The deals align U.S. prescription prices with the lowest prices available in peer developed nations and extend the MFN construct to state Medicaid programs. Companies also pledged manufacturing investments and, in some cases, donations of active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve. For biotech and pharma, the update further extends the policy perimeter around pricing benchmarks and supply-side commitments, widening the number of companies subject to these voluntary constraints.